A Retrospective Study On Diabetes Mellitus, Metformin, And Head And Neck Cancer.

Abstract

Background-More research was needed to determine whether metformin use could impact the risk of oral cancer. Methods: During 2015-2025, patients with type 2 diabetes mellitus who had recently started taking metformin (n = 288198, “ever users of metformin”) or other antidiabetic medications (n = 16263, “never users of metformin”) were monitored for oral cancer for at least six months until December 31, 2011.Cox regression adjusted for propensity score (PS) or integrated with the inverse probability of treatment weighting (IPTW) using PS was used to evaluate the treatment impact of metformin (forever versus never users, and for tertiles of cumulative length of therapy). Results- There were also 1273 (0.44%) and 119 (0.73%) occurrence cases of cancer of the mouth among ever users and never users, respectively, with rates of 92.7 and 163.6 per 100,000 person-years. A substantially decreased risk was indicated by the overall hazard ratios (95% CIs) [0.584 (0.483-0.707) for the PS-added model and 0.562 (0.465-0.678) for the IPTW approach]. The PS-adjusted hazard ratios (95% confidence intervals) for the first (<21.5 months), second (21.5-45.9 months), and third (>45.9 a period of time tertiles of cumulative time span were 1.403 (1.152-1.708), 0.557 (0.453-0.684), and 0.152 (0.119-0.194) for IPTW. Conclusions- The possibility of developing oral cancer may be considerably decreased by metformin, particularly if the cumulative period exceeds 21.5 months.